TY - JOUR
T1 - Advances in Nanomedicine Design
T2 - Multidisciplinary Strategies for Unmet Medical Needs
AU - Ahmed, Taksim
AU - Liu, Fuh Ching Franky
AU - Lu, Brian
AU - Lip, Hoyin
AU - Park, Elliya
AU - Alradwan, Ibrahim
AU - Liu, Jackie Fule
AU - He, Chunsheng
AU - Zetrini, Abdulmottaleb
AU - Zhang, Tian
AU - Ghavaminejad, Amin
AU - Rauth, Andrew M.
AU - Henderson, Jeffrey T.
AU - Wu, Xiao Yu
N1 - Funding Information:
This work is supported in part by the Weston Brain Institute Transformational Grant, University of Toronto Connaught Innovation Award, Killam Research Fellowship by the Canada Council for the Arts, Project Grants from the Canadian Institutes of Health Research, Discovery and Equipment Grants from the Natural Sciences and Engineering Research Council of Canada, JDRF International, and Hemsley Charitable Trust Grants to X.Y.W. The authors also acknowledge the University of Toronto Connaught International Scholarship for Doctoral Students and the Pfizer Canada Graduate Fellowship in Pharmaceutical Sciences to T.A., the Centre for Collaborative Drug Research Graduate Student Incentive Fund to X.Y.W., the Ontario Graduate Scholarship (OGS) to B.L. and T.Z., the Queen Elizabeth Award to B.L. and H.Y.L., the Pharmaceutical Sciences Graduate Student Association Fellowship to E.P., King Abdulaziz City for Science and Technology (KACST) for the scholarship to I.A., Libyan Ministry of Higher Education scholarship to A.Z., Mitacs Accelerate Intership to F.J.L., the BBDC Seller Fellowship to A.GN., and the Mitacs Accelerate Fellowship to K.C.
Publisher Copyright:
© 2022 American Chemical Society. All rights reserved.
PY - 2022/6/6
Y1 - 2022/6/6
N2 - Globally, a rising burden of complex diseases takes a heavy toll on human lives and poses substantial clinical and economic challenges. This review covers nanomedicine and nanotechnology-enabled advanced drug delivery systems (DDS) designed to address various unmet medical needs. Key nanomedicine and DDSs, currently employed in the clinic to tackle some of these diseases, are discussed focusing on their versatility in diagnostics, anticancer therapy, and diabetes management. First-hand experiences from our own laboratory and the work of others are presented to provide insights into strategies to design and optimize nanomedicine- and nanotechnology-enabled DDS for enhancing therapeutic outcomes. Computational analysis is also briefly reviewed as a technology for rational design of controlled release DDS. Further explorations of DDS have illuminated the interplay of physiological barriers and their impact on DDS. It is demonstrated how such delivery systems can overcome these barriers for enhanced therapeutic efficacy and how new perspectives of next-generation DDS can be applied clinically.
AB - Globally, a rising burden of complex diseases takes a heavy toll on human lives and poses substantial clinical and economic challenges. This review covers nanomedicine and nanotechnology-enabled advanced drug delivery systems (DDS) designed to address various unmet medical needs. Key nanomedicine and DDSs, currently employed in the clinic to tackle some of these diseases, are discussed focusing on their versatility in diagnostics, anticancer therapy, and diabetes management. First-hand experiences from our own laboratory and the work of others are presented to provide insights into strategies to design and optimize nanomedicine- and nanotechnology-enabled DDS for enhancing therapeutic outcomes. Computational analysis is also briefly reviewed as a technology for rational design of controlled release DDS. Further explorations of DDS have illuminated the interplay of physiological barriers and their impact on DDS. It is demonstrated how such delivery systems can overcome these barriers for enhanced therapeutic efficacy and how new perspectives of next-generation DDS can be applied clinically.
KW - blood-brain barrier (BBB)-penetrating
KW - multitargeted drug delivery
KW - nanomedicine
KW - polymer lipid hybrid nanoparticles (PLN)
KW - stimulus-responsive drug release
KW - synergistic drug combination
KW - tumor microenvironment modulation
UR - http://www.scopus.com/inward/record.url?scp=85131560483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131560483&partnerID=8YFLogxK
U2 - 10.1021/acs.molpharmaceut.2c00038
DO - 10.1021/acs.molpharmaceut.2c00038
M3 - Review article
C2 - 35587783
AN - SCOPUS:85131560483
SN - 1543-8384
VL - 19
SP - 1722
EP - 1765
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
IS - 6
ER -
